Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

ABSTRACT:

Background

Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs failure-free survival for those without. To date there has been no formal assessment of whether funding docetaxel in this setting represents an appropriate use of UK National Health Service (NHS) resources.

Objective

To assess whether administering docetaxel to men with PC starting long-term hormone therapy is cost-effective in a UK setting.

Design, setting, and participants

We modelled health outcomes and costs in the UK NHS using data collected within the STAMPEDE trial, which enrolled men with high-risk, locally advanced m

SUBMITTER: Woods BS 

PROVIDER: S-EPMC6692495 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature